PURPOSE: Evaluate the incidence of aberrant endometrial integrin (alphavbeta(3) vitronectin) expression in patients at high risk for implantation defects. MATERIALS AND METHODS: Retrospective case-control trial of 74 consecutive infertile patients with prior failed IVF cycles despite good embryo quality and/or endometriosis who underwent endometrial biopsy 9-11 days after an LH surge to assess the presence or absence of alphavbeta(3) vitronectin. Patients were separated into two groups for analysis based on the presence (Gr. A) or absence (Gr. B) of integrin expression. A subset of Gr. B patients (86.1%) was treated with a 2 month course of a GnRH agonist prior to IVF (Gr. B1). No Gr. A patients were so treated. RESULTS: Absent alphavbeta(3) vitronectin expression was noted in 48.6% of patients evaluated. A trend towards more severe endometriosis was noted in Gr. B (57.1 vs 31.5%). Responses to controlled ovarian hyperstimulation and IVF cycle outcomes including ongoing pregnancy rates were similar between Gr. B1 patients untreated Gr. A controls (55.6 vs 63.9%). CONCLUSIONS: A high incidence of absent endometrial alphavbeta(3) vitronectin expression is noted in patients at increased risk for implantation defects. Prolonged GnRH agonist therapy prior to an IVF cycle resulted in outcomes similar to untreated controls with positive expression.
PURPOSE: Evaluate the incidence of aberrant endometrial integrin (alphavbeta(3) vitronectin) expression in patients at high risk for implantation defects. MATERIALS AND METHODS: Retrospective case-control trial of 74 consecutive infertilepatients with prior failed IVF cycles despite good embryo quality and/or endometriosis who underwent endometrial biopsy 9-11 days after an LH surge to assess the presence or absence of alphavbeta(3) vitronectin. Patients were separated into two groups for analysis based on the presence (Gr. A) or absence (Gr. B) of integrin expression. A subset of Gr. B patients (86.1%) was treated with a 2 month course of a GnRH agonist prior to IVF (Gr. B1). No Gr. A patients were so treated. RESULTS: Absent alphavbeta(3) vitronectin expression was noted in 48.6% of patients evaluated. A trend towards more severe endometriosis was noted in Gr. B (57.1 vs 31.5%). Responses to controlled ovarian hyperstimulation and IVF cycle outcomes including ongoing pregnancy rates were similar between Gr. B1patients untreated Gr. A controls (55.6 vs 63.9%). CONCLUSIONS: A high incidence of absent endometrial alphavbeta(3) vitronectin expression is noted in patients at increased risk for implantation defects. Prolonged GnRH agonist therapy prior to an IVF cycle resulted in outcomes similar to untreated controls with positive expression.
Authors: Montserrat Creus; Jaume Ordi; Francisco Fábregues; Roser Casamitjana; Francisco Carmona; Antonio Cardesa; Juan A Vanrell; Juan Balasch Journal: Hum Reprod Date: 2003-04 Impact factor: 6.918
Authors: B A Lessey; A J Castelbaum; S W Sawin; C A Buck; R Schinnar; W Bilker; B L Strom Journal: J Clin Endocrinol Metab Date: 1994-08 Impact factor: 5.958
Authors: Ahmed Elnaggar; Amr H Farag; Mohamed E Gaber; Mohamed Abdel Hafeez; Mohamed S Ali; Alaa M Atef Journal: BMC Womens Health Date: 2017-09-26 Impact factor: 2.809
Authors: Maria Szubert; Edward Koziróg; Olga Olszak; Klaudia Krygier-Kurz; Jakub Kazmierczak; Jacek Wilczynski Journal: Int J Environ Res Public Health Date: 2021-01-30 Impact factor: 3.390